Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

Recursion Pharmaceuticals RXRX announced that it has dosed the first patient in its early-stage study of investigational ...

Permanent Portfolio Aggressive Gr Port earns an Average Process Pillar rating. The main driver of the rating is the firm's retention rate of the firm's portfolio managers, which is 100% over the ...